Reaction Details Report a problem with these data
Target
NT-3 growth factor receptor
Ligand
BDBM50565738
Substrate
n/a
Meas. Tech.
ChEMBL_2093490 (CHEMBL4774753)
EC50
29±n/a nM
Citation
Wang, B; Zhang, W; Liu, X; Zou, F; Wang, J; Liu, Q; Wang, A; Hu, Z; Chen, Y; Qi, S; Jiang, Z; Chen, C; Hu, C; Wang, L; Wang, W; Liu, Q; Liu, J Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants. Eur J Med Chem 207:0 (2020) [PubMed] Article
More Info.:
Target
Name:
NT-3 growth factor receptor
Synonyms:
GP145-TrkC | NTRK3 | NTRK3_HUMAN | Neurotrophic tyrosine kinase receptor | Neurotrophic tyrosine kinase receptor type 3 | TRKC | Trk-C | TrkC tyrosine kinase | Tyrosine kinase receptor C (Trk-C)
Type:
Enzyme
Mol. Mass.:
94428.15
Organism:
Homo sapiens (Human)
Description:
Q16288
Residue:
839
Sequence:
MDVSLCPAKCSFWRIFLLGSVWLDYVGSVLACPANCVCSKTEINCRRPDDGNLFPLLEGQDSGNSNGNASINITDISRNITSIHIENWRSLHTLNAVDMELYTGLQKLTIKNSGLRSIQPRAFAKNPHLRYINLSSNRLTTLSWQLFQTLSLRELQLEQNFFNCSCDIRWMQLWQEQGEAKLNSQNLYCINADGSQLPLFRMNISQCDLPEISVSHVNLTVREGDNAVITCNGSGSPLPDVDWIVTGLQSINTHQTNLNWTNVHAINLTLVNVTSEDNGFTLTCIAENVVGMSNASVALTVYYPPRVVSLEEPELRLEHCIEFVVRGNPPPTLHWLHNGQPLRESKIIHVEYYQEGEISEGCLLFNKPTHYNNGNYTLIAKNPLGTANQTINGHFLKEPFPESTDNFILFDEVSPTPPITVTHKPEEDTFGVSIAVGLAAFACVLLVVLFVMINKYGRRSKFGMKGPVAVISGEEDSASPLHHINHGITTPSSLDAGPDTVVIGMTRIPVIENPQYFRQGHNCHKPDTYVQHIKRRDIVLKRELGEGAFGKVFLAECYNLSPTKDKMLVAVKALKDPTLAARKDFQREAELLTNLQHEHIVKFYGVCGDGDPLIMVFEYMKHGDLNKFLRAHGPDAMILVDGQPRQAKGELGLSQMLHIASQIASGMVYLASQHFVHRDLATRNCLVGANLLVKIGDFGMSRDVYSTDYYRLFNPSGNDFCIWCEVGGHTMLPIRWMPPESIMYRKFTTESDVWSFGVILWEIFTYGKQPWFQLSNTEVIECITQGRVLERPRVCPKEVYDVMLGCWQREPQQRLNIKEIYKILHALGKATPIYLDILG